Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-7150
Abegg, M; Tappeiner, C; Wolf-Schnurrbusch, U; Barthelmes, D; Wolf, S; Fleischhauer, J (2008). Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophtalmology, 8:18:1-8.
View at publisher
BACKGROUND: Branch retinal vein occlusion is a frequent cause of visual loss with currently insufficient treatment options. We evaluate the effect of Bevacizumab (Avastin) treatment in patients with macular edema induced by branch retinal vein occlusion. METHODS: Retrospective analysis of 32 eyes in 32 patients with fluorescein angiography proven branch retinal vein occlusion, macular edema and Bevacizumab treatment. Outcome measures were best corrected visual acuity in logMAR and central retinal thickness in OCT. RESULTS: Visual acuity was significantly better 4 to 6 weeks after Bevacizumab treatment compared to visual acuity prior to treatment (before 0.7 +/- 0.3 and after 0.5 +/- 0.3; mean +/- standard deviation; p < 0.01, paired t-test). Gain in visual acuity was accompanied by a significant decrease in retinal thickness (454 +/- 117 to 305 +/- 129 microm, p < 0.01, paired t-test). Follow up (170, 27 - 418 days; median, range) shows that improvement for both visual acuity and retinal thickness last for several months after Bevacizumab use. CONCLUSION: We present evidence that intravitreal Bevacizumab is an effective and lasting treatment for macular edema after branch retinal vein occlusion.
242 downloads since deposited on 09 Dec 2008
66 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Ophthalmology Clinic|
|Dewey Decimal Classification:||610 Medicine & health|
|Date:||29 September 2008|
|Deposited On:||09 Dec 2008 08:02|
|Last Modified:||27 Nov 2013 18:11|
|Additional Information:||Free full text article|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page